Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings...read more
Global Blood Therapeutics became the fifth IPO of 2015 to pop more than 100% on its first day. Year-to-date, 130 IPOs have raised $22 billion, or 31% fewer IPOs...read more
Houlihan Lokey, a leading mid-cap focused independent investment bank, raised $221 million by offering 10.5 million shares at $21, below the range of $22 to $24. Selling shareholders floated the entire IPO. Houlihan had originally planned to raise $300...read more
It's the final push for US IPOs before a four-week lull that should end in mid-September. Five IPOs are on the calendar this week, plus two blank check companies. Sickle cell...read more
US IPO Week Ahead: The IPO market takes a breather in a 4 IPO week
Updated Monday, 8/10 After an active July, the US IPO market is taking a breather. Three companies are scheduled to raise $2.5 billion in the week ahead, led by Chinese real estate giant KE Holdings (BEKE). KE Holdings...read more
US IPO Weekly Recap: Sickle cell biotech pops 100% and investment bank goes public
Global Blood Therapeutics became the fifth IPO of 2015 to pop more than 100% on its first day.
Year-to-date, 130 IPOs have raised $22 billion, or 31% fewer IPOs...read more
Investment bank Houlihan Lokey prices downsized IPO below the range at $21
Houlihan Lokey, a leading mid-cap focused independent investment bank, raised $221 million by offering 10.5 million shares at $21, below the range of $22 to $24. Selling shareholders floated the entire IPO. Houlihan had originally planned to raise $300...read more
Week ahead: 5 IPOs set to price during the week of August 10
It's the final push for US IPOs before a four-week lull that should end in mid-September. Five IPOs are on the calendar this week, plus two blank check companies. Sickle cell...read more